# The Safety and Effectiveness of Transcatheter Aortic Valve Raplacemet in Intermediate Risk Patients With Bicuspid Aortic Stenosis

Study · id `cardio:ct-nct03163329` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03163329](<https://clinicaltrials.gov/study/NCT03163329>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03163329

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT03163329. Randomized; single masking; primary purpose treatment. Start 2018-02-01 (anticipated); primary completion 2020-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT03163329, source copy `cardio:ctgov-nct03163329-2018-01-11`, retrieved 2026-10-26)
- Planned start: 2018-02-01 (anticipated) (ClinicalTrials.gov record NCT03163329, source copy `cardio:ctgov-nct03163329-2018-01-11`, retrieved 2026-10-26)
- Primary completion: 2020-10-31 (anticipated) (ClinicalTrials.gov record NCT03163329, source copy `cardio:ctgov-nct03163329-2018-01-11`, retrieved 2026-10-26)
- Completion: 2024-10-31 (anticipated) (ClinicalTrials.gov record NCT03163329, source copy `cardio:ctgov-nct03163329-2018-01-11`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03163329-2018-01-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Safety and Effectiveness of Transcatheter Aortic Valve Raplacemet in Intermediate Risk Patients With Bicuspid Aortic Stenosis
- Condition: Aortic Valve Disease
- Intervention (Procedure): TAVR
- Intervention (Procedure): SAVR
- Lead sponsor: China National Center for Cardiovascular Diseases
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: China National Center for Cardiovascular Diseases (`cardio:org-china-national-center-for-cardiovascular-diseases`)

## Provenance

Content hash: 4797bc8aa422a356c8c169e6de91652e8600ba82ebf55e31d7f6dcc21177723b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
